文献速递浆细胞疾病

中国新诊断多发性骨髓瘤患者风险分层、治疗模式与生存结局的真实世界分析

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee.
PubMed 文献 · Br J Haematol · 2026-07-26

基于中国骨髓瘤委员会10家中心1384例新诊断多发性骨髓瘤患者的真实世界分析,中位年龄62岁。RVD方案成为主要诱导方案(51.8%),≤65岁患者一线自体造血干细胞移植率升至40.0%。中位随访46.6个月,中位生存未达到,估计4年生存率66.4%;2025 CGS高危患者占26.2%,携带≥2个CGS高危因素者(3.8%)预后显著更差。

要点

  • 中国骨髓瘤患者中位年龄62岁,较西方人群年轻。
  • RVD为最主要诱导方案(51.8%),≤65岁患者一线移植率达40.0%。
  • 2025 CGS高危占26.2%,≥2个高危因素者(3.8%)预后显著更差。

核心结论

  • 现代三联方案广泛采用与中国真实世界骨髓瘤患者生存改善相关。
  • 2025 IMS/IMWG CGS在亚洲队列中得到验证,携带多个CGS高危因素者预后显著不良。

研究设计与样本

  • 中国骨髓瘤委员会10家代表性中心的真实世界分析,纳入1384例新诊断多发性骨髓瘤患者。
  • 生存结局经国家死因监测系统核实以确保数据准确性。
  • 两个中心子队列用于分析无进展生存,总体队列中位随访46.6个月。

主要发现

  • 中位年龄62岁。
  • RVD方案占诱导治疗的51.8%。
  • ≤65岁患者一线自体造血干细胞移植率为40.0%,既往多中心研究为20.0%。
  • 两个中心子队列中位无进展生存44.2个月。
  • 总体队列中位生存未达到,估计4年生存率66.4%;2025 CGS高危占26.2%,≥2个CGS高危因素者占3.8%且预后显著更差。

关键数值与推荐

  • 采用2025 IMS/IMWG共识基因组分期(CGS)进行风险分层,高危占26.2%。
  • 携带≥2个CGS高危因素者占3.8%,预后显著更差。

临床怎么用

  • 中国新诊断骨髓瘤患者应关注较西方更年轻的中位发病年龄。
  • RVD三联方案和≤65岁患者一线自体移植是当前真实世界的主要治疗模式。
  • 可采用2025 CGS识别高危患者,尤其是携带≥2个高危因素者需更密切监测。

局限性

  • 无进展生存仅来自两个中心子队列,非总体队列数据。
  • 总体队列中位随访46.6个月,中位生存未达到,长期结局需更久随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We analysed 1384 newly diagnosed multiple myeloma patients from 10 representative centres of the Chinese Myeloma Committee to provide an important modern real-world reference. Survival outcomes were verified by the National Mortality Surveillance System to ensure data accuracy. The median age was 62 years, confirming a younger age at onset in Chinese patients than in Western populations. Treatment patterns have evolved significantly: Lenalidomide, bortezomib and dexamethasone (RVD) became the predominant induction regimen (51.8%), and upfront autologous haematopoietic stem cell transplantation (AHSCT) rates in patients aged ≤65 years rose to 40.0% (vs. 20.0% in our previous multicentre study). In a subcohort of patients from two out of the 10 sites, the median progression-free survival was 44.2 months. In the overall multicentre cohort, the median survival was not reached during a median follow-up of 46.6 months, with an estimated 4-year survival rate of 66.4%. Using the 2025 International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) Consensus Genomic Staging (CGS), 26.2% of patients were classified as high risk. Patients harbouring ≥2 CGS high-risk factors (3.8%) had significantly inferior prognosis. This study validates the 2025 CGS in an Asian cohort and suggests that the widespread adoption of modern triplets is associated with improved real-world survival, while highlighting the distinct poor outcomes in patients with multiple CGS risk factors.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dou X, Liao A, Luo J, et al. Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee. Br J Haematol. 2026. PMID: 42502998. doi:10.1111/bjh.70712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。